Correlation between chemotherapy cycles and performance status based on ECOG in non-small cell lung cancer patients
DOI:
https://doi.org/10.52830/inajcc.v2i1.62Keywords:
chemotherapy cycle, performance status, non-small cell lung carcinomaAbstract
Background: The prevalence of lung cancer incidence is 14.3% in men and 8.4% in women. Smoking is one of the causes of lung cancer. Chemotherapy is a treatment for NSCLC and affects to the performance status patients.
Aim: This study is to determine the relationship between chemotherapy cycles and performance status based on ECOG in non-small cell carcinoma (NSCLC) lung cancer patients at dr. Zainoel Abidin Banda Aceh in 2017-2020.
Method: This is an observational analytic study with cross sectional design with total sampling method and data sourced from medical records as many as 164 subjects.
Result: The results showed that 57% of NSCLC patients after chemotherapy had a stable performance status while the other 41% decreased. The carboplatin + paclitaxel regimen is the most widely used regimen (43%) and shows average PFS < 1 year dan OS < 2 years.
Conclusion: Based on bivariate analysis using the Spearman method, obtained p-value <0.05 with an R value of 0.367 which indicates there is a relationship between chemotherapy cycles and performance status based on ECOG in NSCLC patients at RSUD dr. Zainoel Abidin with a low correlation coefficient.
Downloads
Published
License
Copyright (c) 2023 NOVITA ANDAYANI, Diana F Syafni, Mirfandi Amirsyah, Yunita Arliny, Rima Novirianthy, Murtaza

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.




